A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
Erectile Dysfunction, Prostate Cancer
About this trial
This is an interventional prevention trial for Erectile Dysfunction focused on measuring Treatment effectiveness, Treatment efficacy, Investigational, Therapies, Immunosuppressant, Erectile dysfunction, Prostatectomy
Eligibility Criteria
Inclusion Criteria: Male scheduled to undergo bilateral nerve sparing radical prostatectomy for prostate cancer. Exclusion Criteria: Patient is > 65 years of age Patient has been diagnosed with Type 1 or Type 2 diabetes Patient is actively smoking on a daily basis
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Tacrolimus
Placebo
Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.